PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10912316-1 2000 Ramipril is a long-acting, lipophylic angiotensin converting enzyme inhibitor, its principle action is to inhibit the conversion of angiotensin I to the active angiotensin II. Ramipril 0-8 angiotensinogen Homo sapiens 132-145 27006715-0 2015 Angiotensinogen (AGT) M235T, AGT T174M and Angiotensin-1-Converting Enzyme (ACE) I/D Gene Polymorphisms in Essential Hypertension: Effects on Ramipril Efficacy. Ramipril 142-150 angiotensinogen Homo sapiens 0-15 24154707-15 2014 Ramipril significantly decreased angiotensin II concentration. Ramipril 0-8 angiotensinogen Homo sapiens 33-47 24070321-7 2013 EXPERT OPINION: Azilsartan medoxomil has a potent and persistent ability to inhibit binding of angiotensin II to AT1 receptors, which may play a role in its superior blood pressure (BP) -lowering efficacy compared with other drugs, including ramipril, candesartan, valsartan or olmesartan, without an increase of side effects. Ramipril 242-250 angiotensinogen Homo sapiens 95-109 11717612-10 2001 Ramipril decreased plasma levels of angiotensin II at 3 days but had no effect on the other neurohormones. Ramipril 0-8 angiotensinogen Homo sapiens 36-50 27006715-4 2015 Furthermore, we evaluated the effect of ACE and AGT gene polymorphisms on ramipril treatment efficacy in the hypertensive patients. Ramipril 74-82 angiotensinogen Homo sapiens 48-51 19587554-2 2009 The recent ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) has shown that, in patients with vascular disease or patients with diabetes who were at high risk of cardiovascular events, the angiotensin II receptor blocker telmisartan is noninferior to the angiotensin-converting enzyme inhibitor ramipril in preventing such events, despite the ONTARGET patients receiving better background preventive therapy than those enrolled in the earlier Heart Outcomes Prevention Evaluation (HOPE) study. Ramipril 61-69 angiotensinogen Homo sapiens 231-245 19587554-2 2009 The recent ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) has shown that, in patients with vascular disease or patients with diabetes who were at high risk of cardiovascular events, the angiotensin II receptor blocker telmisartan is noninferior to the angiotensin-converting enzyme inhibitor ramipril in preventing such events, despite the ONTARGET patients receiving better background preventive therapy than those enrolled in the earlier Heart Outcomes Prevention Evaluation (HOPE) study. Ramipril 337-345 angiotensinogen Homo sapiens 231-245 19196886-4 2009 RESULTS: Ramipril decreased systolic and diastolic blood pressure, ACE activity, and angiotensin II and increased plasma renin activity. Ramipril 9-17 angiotensinogen Homo sapiens 85-99 12754187-6 2004 Administration of an ACE inhibitor (ramipril) reduced ACE activity, ANG II concentration, TGF-beta expression, and collagen deposition. Ramipril 36-44 angiotensinogen Homo sapiens 68-74 10912316-1 2000 Ramipril is a long-acting, lipophylic angiotensin converting enzyme inhibitor, its principle action is to inhibit the conversion of angiotensin I to the active angiotensin II. Ramipril 0-8 angiotensinogen Homo sapiens 160-174 9607375-9 1998 Ramipril caused a sustained fall in plasma angiotensin II, whereas HCTZ increased angiotensin II levels. Ramipril 0-8 angiotensinogen Homo sapiens 43-57 9612217-7 1998 Ramipril therapy was associated with functional alterations: vasoconstrictor responses to norepinephrine and angiotensin II were significantly enhanced compared with placebo (P < 0.001). Ramipril 0-8 angiotensinogen Homo sapiens 109-123 11967789-12 2000 Possible explanations for the non BP-mediated benefits of ramipril include reduction of angiotensin II-induced intimal and vascular smooth muscle proliferation and possible plaque stabilisation. Ramipril 58-66 angiotensinogen Homo sapiens 88-102 2474107-2 1989 Captopril, alacepril, ramipril, and altiopril administered in single doses rapidly decreased blood pressure and plasma angiotensin II levels, and increased plasma and urinary kinins as well as plasma renin activity. Ramipril 22-30 angiotensinogen Homo sapiens 119-133 1302161-5 1992 Ang II values dropped as expected on the first day of ramipril treatment from 11.2 pg/ml to 2.9 pg/ml at 3 h post administration and from 6.7 pg/ml (predose) to 1.8 pg/ml at 2 h post administration on day 15. Ramipril 54-62 angiotensinogen Homo sapiens 0-6 2481181-3 1989 Ramipril resulted in significant falls in converting enzyme activity, angiotensin II, and aldosterone, with a rise in renin. Ramipril 0-8 angiotensinogen Homo sapiens 70-84 8957034-9 1996 Plasma angiotensin II levels decreased with both low- and high-dose ramipril. Ramipril 68-76 angiotensinogen Homo sapiens 7-21 8902551-6 1996 The biological effects of cessation of long-term ramipril treatment in hypertensives were a decline in AR and angiotensin I concentrations, an increase in ACE activity and no significant changes in angiotensinogen, angiotensin II and aldosterone levels. Ramipril 49-57 angiotensinogen Homo sapiens 110-123 2532921-4 1989 Frusemide increased natriuresis (UNaV), kaliuresis (UKV), inulin clearance and plasma renin activity (PRA) and ramipril pretreatment significantly enhanced these effects suggesting that the acute generation of angiotensin II (AII) may attenuate these actions of intravenous frusemide. Ramipril 111-119 angiotensinogen Homo sapiens 210-224 2967740-7 1988 Acute oral administration of the converting-enzyme inhibitor ramipril caused a significant increase of angiotensin I from 85 (+/- 6) to 257 (+/- 33) pmol/L (n = 10; P less than 0.001) and a significant decrease of angiotensin II from 12 (+/- 1) to 7 (+/- 0.4) pmol/L in rat plasma (n = 9; P less than 0.001). Ramipril 61-69 angiotensinogen Homo sapiens 103-116 2953225-0 1987 Influence of ramipril diacid on the peripheral vascular effects of angiotensin I. Ramipril 13-21 angiotensinogen Homo sapiens 67-80 3034025-4 1987 Ramipril induced pronounced, sustained decreases in angiotensin converting enzyme activity, angiotensin II and aldosterone levels, and a reciprocal increase in plasma renin activity. Ramipril 0-8 angiotensinogen Homo sapiens 92-106 3034030-3 1987 Ramipril lowers blood pressure in various models of hypertension and improves states of acute cardiac failure mainly by suppression of angiotensin II formation. Ramipril 0-8 angiotensinogen Homo sapiens 135-149 32507039-6 2020 Compared with basally, plasma levels of equilibrium angiotensin I (eqAngI) and direct renin concentration increased significantly (P<0.01 or P<0.05) after ramipril treatment, whereas eqAngII and ACE activity (eqAngII/eqAngI) decreased significantly (P<0.01). Ramipril 155-163 angiotensinogen Homo sapiens 52-65